Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07592780
NA

Pathway to Peanut Tolerance

Sponsor: Chinese University of Hong Kong

View on ClinicalTrials.gov

Summary

While rigorous clinical trials have established peanut OIT as a promising therapy capable of inducing desensitization and even remission, its transition to routine clinical practice requires robust real-world evidence. Current management relies on strict avoidance, and the lack of reliable biomarkers to predict long-term success remains a significant barrier to the wider, more accessible application of OIT. Therefore, there is a critical need to evaluate peanut OIT in pragmatic, real-world settings. Such studies are essential to understand its effectiveness and safety beyond controlled trial conditions, to identify which patients benefit most, and to develop practical monitoring strategies. Generating this evidence is a crucial step toward making this treatment a viable and optimized option for the growing global population affected by peanut allergy.

Official title: A Pragmatic, Open-label Study of Peanut Oral Immunotherapy in Inducing Desensitisation or Remission in Children With Food Allergy Compared to Standard Care (Strict Allergen Avoidance)

Key Details

Gender

All

Age Range

2 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

125

Start Date

2025-11-15

Completion Date

2029-12-31

Last Updated

2026-05-19

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Peanut Oral Immunotherapy (OIT)

This study uses a commercially available, standardized defatted peanut powder as its active intervention

Locations (1)

Department of Paediatrics, Prince of Wales Hospital

Hong Kong, Hong Kong